Global Fusion Biopsy Market Insights Forecasts to 2033

• The Global Fusion Biopsy Market Size was Valued at USD 565.5 Million in 2023.
• The Market Size is Growing at a CAGR of 8.4% from 2023 to 2033.
• The Worldwide Fusion Biopsy Market Size is Expected to Reach USD 1266.8 Million by 2033.
• Europe is expected to grow the fastest during the forecast period.

The Global Fusion Biopsy Market Size is Anticipated to Exceed USD 1266.8 Million by 2033, Growing at a CAGR of 8.4% from 2023 to 2033.

Market Overview

Fusion biopsy, also known as targeted biopsy, uses MRI and ultrasound to guide precise and accurate biopsies. A fusion biopsy creates a 3-D image of the prostate gland by combining images from an MRI and an ultrasound. This procedure makes it easier to visualize an abnormal tissue area so that the biopsy needle can be guided into it. Before the fusion biopsy, medical professionals would take random samples from various prostate regions. The MRI/ultrasound fusion biopsy begins with a prostate MRI performed on a 3T MRI. This initial exam will be read by a radiologist, who will look for any abnormalities that could indicate cancer. The biopsy can be scheduled separately from the diagnostic MRI. On the same day, a diagnostic MRI and a biopsy might be performed. If the diagnostic MRI reveals no target, the biopsy could be canceled. Prostate cancer cells that other biopsies could miss could be found with fusion biopsies. Planning for early cancer detection and treatment could profit from it. Another name for it is fusion-guided MRI ultrasound biopsy.

Report Coverage

This research report categorizes the market for the global fusion biopsy market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global fusion biopsy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global fusion biopsy market.

Driving Factors

The rising incidence of prostate cancer is a key market driver for the global fusion biopsy market. Prostate cancer is one of the most common cancers in men worldwide, and its rising prevalence has significant implications for the demand and use of fusion biopsy techniques. The global incidence of prostate cancer has steadily increased over the last few decades. This can be attributed to a variety of factors, including aging populations, changing lifestyles, and improved diagnostic methods for detecting prostate cancer earlier. With a larger pool of potential patients, there is a greater need for accurate and efficient diagnostic tools, such as fusion biopsy. Advancements in imaging technologies are a key market driver for the global fusion biopsy market. Fusion biopsy, which combines MRI and ultrasound, is heavily reliant on technological advances to provide precise and real-time guidance for targeted prostate biopsies.

Restraining Factors

Fusion biopsy, which involves the use of advanced imaging technologies, can be more expensive than traditional biopsy methods. The cost of MRI machines, specialized software, and the additional expertise needed to perform fusion biopsies can be significant obstacles. As a result, healthcare facilities might be hesitant to invest in fusion biopsy equipment, leaving patients with higher medical bills or limited insurance coverage. Fusion biopsy necessitates access to advanced medical equipment, skilled healthcare professionals, and supportive infrastructure. In many parts of the world, particularly in rural or underserved areas, access to such resources might be limited.

Market Segmentation

The global fusion biopsy market share is classified into biopsy route and end-user.

• The transrectal segment is expected to hold the largest share of the global fusion biopsy market during the forecast period.   

Based on the biopsy route, the global fusion biopsy market is categorized into transrectal and transperineal. Among these, the transrectal segment is expected to hold the largest share of the global fusion biopsy market during the forecast period. Most commercially available fusion biopsy techniques are limited to the transrectal approach, which contributes to its market dominance. However, reports of fever, sepsis, hematuria, and rectal bleeding following transrectal fusion biopsy have resulted in sluggish market growth for this segment.

• The hospitals segment is expected to hold a significant share of the fusion biopsy market during the forecast period.   

Based on the end-user, the global fusion biopsy market is categorized into hospitals, diagnostic centers, and ambulatory care centers. Among these, the hospitals segment is expected to hold the largest share of the global fusion biopsy market during the forecast period due to their high purchasing power. A fusion biopsy system has a high average unit price, making it unaffordable for private diagnostic centers. However, as demand for prostate cancer care in rural areas grows, the use of these systems in ambulatory care centers is expected to increase. The continuity of care provided by hospitals improves the patient experience and the effectiveness of fusion biopsy as a diagnostic tool. Hospitals frequently have close ties with academic and research institutions.

Regional Segment Analysis of the Global Fusion Biopsy Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global fusion biopsy market over the predicted timeframe.

North America is projected to hold the largest share of the global fusion biopsy market over the predicted timeframe. North America has a very developed and advanced healthcare infrastructure. This includes a vast network of hospitals, clinics, and diagnostic facilities outfitted with cutting-edge medical technology. Fusion biopsy, which necessitates advanced imaging equipment and specialized knowledge, is more widely available in this region. Prostate cancer is a major health concern in North America, with a high prevalence rate. The prevalence of this cancer raises the need for precise and dependable diagnostic tools such as fusion biopsy. Given the emphasis on early detection and treatment, fusion biopsy is an important part of the region's healthcare system. North America has a significant pool of skilled healthcare professionals, including urologists and radiologists, who are essential for performing and correctly interpreting fusion biopsy procedures.

Europe market is expected to grow at the fastest CAGR growth during the forecast period. Factors such as Europe have seen an increase in awareness campaigns and initiatives to promote early cancer detection. Prostate cancer awareness and screening programs have gained traction, resulting in an increase in patients seeking diagnostic services such as fusion biopsy. Europe has made investments in improving its healthcare infrastructure, particularly in countries with advanced healthcare systems. The purchase of modern imaging equipment and the expansion of healthcare facilities contribute to the growth of fusion biopsy services.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global fusion biopsy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Eigen Health
• Koninklijke Philips N.V.
• Hitachi Ltd.
• MedCom
• ESAOTE SpA
• KOELIS
• Focal Healthcare
• UC-Care Medical Systems Ltd.
• GeoScan Medical
• Esaoate SpA
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In May 2022, Koelis, SAS, a leader and innovator in prostate care, has announced the availability of new Trinity 3D ultrasound and MRI fusion platform features. The Koelis Trinity system combines 3D ultrasound imaging with proprietary MRI-US fusion image guidance, which includes the company's proprietary prostate motion tracking software (OBT Fusion).

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global fusion biopsy market based on the below-mentioned segments: 

Global Fusion Biopsy Market, By Biopsy Route

• Transrectal
• Transperineal

Global Fusion Biopsy Market, By End-User

• Hospitals
• Diagnostic Centers
• Ambulatory Care Centers

Global Fusion Biopsy Market, Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa